Outcome definition | Number of persons | Number of | Crude incidence | HR* |
---|---|---|---|---|
Cohort | at risk | events | per 10,000 pys | |
First invasive solid or hematologic malignancy excluding NMSC | ||||
Tocilizumab | 1408 | 30 | 80 | 0.78 (0.54–1.12) |
Abatacept | 1565 | 45 | 104 | 0.95 (0.70–1.28) |
Rituximab | 2793 | 108 | 103 | 0.86 (0.70–1.04) |
First TNFi | 9355 | 369 | 93 | 0.91 (0.82–1.01) |
Second TNFi | 3610 | 129 | 87 | 0.88 (0.73–1.05) |
csDMARD RA | 40071 | 2797 | 131 | 1 (reference) |
*Adjusted for age, sex, disease- and treatment characteristics, and educational level.